News

Charité Research Organisation GmbH has experience in the conduct of early phase projects for new anti-obesity drugs. We want to share our expertise in this special Whitepaper that comes in three parts. 

Many new drug candidates for obesity and related diseases will be discussed according to their development phase in these Whitepapers.

In Part 3, the diverse phenotypes of heart failure (HF) will be discussed with a special focus on the cardiometabolic phenotype of HF with preserved ejection fraction (HFpEF), in which chronic cardiometabolic stress resulting from T2DM and/or obesity are key drivers of HF pathophysiology. The new treatment options for HFpEF with or without obesity will be described including a discussion of the recent class I recommendation for the SGLT2 inhibitors empagliflozin and dapagliflozin [2023 Focused Update of the European Society of Cardiology Guideline in 2021].

Author and Contact:
Claudia Werner, MD, PhD
Charité Research Organisation GmbH
Charitéplatz 1, 10117 Berlin
claudia.werner@charite-research.org